URGN
UroGen Pharma Ltd.
URGN lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
URGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
URGN's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
URGN PE Valuation
URGN has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
URGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect URGN to return to profit, with revenue growing. However, they disagree widely on these estimates.
URGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.79 | — |
| Q3 2026 | -$1.33 | +$2.13 |
| Q2 2026 | -$1.99 | +$1.33 |
| Q1 2026 | -$2.76 | +$0.42 |
| Q4 2025 | -$3.21 | +$0.02 |
| Q3 2025 | -$3.46 | -$0.13 |
| Q2 2025 | -$3.32 | +$0.14 |
| Q1 2025 | -$3.18 | +$0.40 |
| Q4 2024 | -$3.23 | +$0.68 |
URGN is still losing money, but far less than before: $1.33 per share over the past year, against $6.40 at its worst in late 2020.
URGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $89M | +224% |
| Q2 2026 | $72.5M | +199% |
| Q1 2026 | $51M | +152% |
| Q4 2025 | $37.8M | +54% |
| Q3 2025 | $27.5M | +9% |
| Q2 2025 | $24.2M | +11% |
| Q1 2025 | $20.3M | +7.8% |
| Q4 2024 | $24.6M | +4.4% |
URGN's revenue has grown year over year every quarter since early 2021: $89M last quarter, up 224% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.4% | +109 points |
| Q2 2026 | 0.1% | +171 points |
| Q1 2026 | -40% | +143 points |
| Q4 2025 | -51% | +62 points |
| Q3 2025 | -100% | -30 points |
| Q2 2025 | -171% | -53 points |
| Q1 2025 | -182% | -45 points |
| Q4 2024 | -113% | -51 points |
URGN's operating margin was 9.4% last quarter, up 109 points from the same quarter a year ago, near the top of its range since 2020.
URGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.3M | +$27.1M |
| Q2 2026 | -$33.1M | +$6.9M |
| Q1 2026 | -$45.4M | -$3.3M |
| Q4 2025 | -$38.3M | -$24.6M |
| Q3 2025 | -$42.4M | -$14.6M |
| Q2 2025 | -$40M | -$16.1M |
| Q1 2025 | -$42.1M | -$10.3M |
| Q4 2024 | -$13.7M | -$682K |
URGN has burned cash in almost every quarter: −$132M over the past year, against −$138M the year before.
URGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +178K shares |
| 1 year | +5.2% | +2.5M shares |
| 3 years | +115% | +27.1M shares |
| 5 years | +126% | +28.2M shares |
| Available history | +146% | +30M shares |
URGN has 51M diluted shares, up 5.2% from a year ago.
URGN Net Leverage
URGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
URGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 3.5 | Oversold |
URGN's weekly RSI is 36 (neutral) and its Stochastic is 4 (oversold).
URGN PE vs Healthcare Sector
URGN has no meaningful PE right now: it lost money over the past year.
URGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.1 | 23% below |
| 20 week MA | $39.2 | 33% below |
| 50 week MA | $29.7 | 11% below |
| 100 week MA | $21.9 | 20% above |
| 200 week MA | $17.7 | 49% above |
URGN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 49% above its 200-week average.
URGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.1 | $18.9 | -43% |
| 2021 | $18.9 | $9.49 | -50% |
| 2022 | $9.49 | $8.14 | -14% |
| 2023 | $8.14 | $15.0 | +84% |
| 2024 | $15.0 | $10.8 | -28% |
| 2025 | $10.8 | $23.0 | +114% |
| 2026 YTD | $23.0 | $26.4 | +15% |
URGN's yearly returns have swung widely, from +114% in 2025 to −50% in 2021. It's up 15% so far in 2026.